Life Extension Super Ubiquinol CoQ10 with PrimaVie Shilajit is the highest-plasma-Q10 bottle on the consumer market. The formulation stacks two patent-grade ingredients in one softgel: 100 mg licensed Kaneka QH ubiquinol (the reduced form with 2-4× bioavailability advantage over ubiquinone in adults 40+) plus 100 mg PrimaVie shilajit (the standardised Himalayan resin with published 29-39% additional absorption gains versus ubiquinol alone, Keller 2014). At $45 for 60 softgels at 1/day, it's the most expensive ubiquinol per active mg on the list — but the premium buys you measurably higher plasma Q10 than any single bottle achievable without the shilajit carrier. Eight weeks running 1 softgel with dinner, here's the full breakdown.
Check on AmazonAffiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete CoQ10 guide →Licensed Kaneka QH ubiquinol — the reduced, pre-converted form with 2-4× bioavailability advantage in adults 40+ (Zhang 2018). The patent-grade Japanese fermentation-derived material used in the academic ubiquinol literature. Maximum form score for the target buyer (50+ longevity, statin users). The PrimaVie shilajit carrier adds a second absorption mechanism on top of the form advantage — stacked optimisation, not just form optimisation.
100 mg Kaneka QH ubiquinol + 100 mg PrimaVie shilajit per softgel — hits the longevity baseline (1 softgel/day) cleanly. At 2 softgels/day for statin protocols you're delivering 200 mg ubiquinol + 200 mg shilajit, which exceeds the trial-dose for both components and approaches diminishing-returns absorption. Slight 0.5-point discount versus Jarrow because the shilajit dose-stacking math is less linear than ubiquinol-alone at higher protocols.
Three layers stacked: licensed Kaneka QH on the supplement-facts panel (verifiable on Kaneka's QH licensed-products registry), licensed PrimaVie shilajit (verifiable on Natreon's PrimaVie registry), and Life Extension's in-house QC discipline (40+ years, in-house clinical-research arm). Life Extension publishes per-batch testing summaries on request, GMP-certified facility, heavy-metals screening on the PrimaVie material specifically. Top-of-class chain-of-custody short of NSF Sport certification.
$45/month at 1 softgel/day = $0.75 per 100 mg ubiquinol + 100 mg shilajit softgel = $0.0075 per active mg ubiquinol. The most expensive ubiquinol per active mg on the entire list — 60% more expensive than Jarrow (#1) at $0.0047/mg, 2.1× the cost of Healthy Origins (#6) at $0.0035/mg. The premium reflects the dual patent-grade ingredients + Life Extension's brand-equity layer, not just the bioactive content. Justified for the target buyer; overkill for the casual user.
The PrimaVie shilajit carrier delivers the highest peak plasma Q10 of any single consumer bottle (Keller 2014: ~29-39% higher than ubiquinol-alone at equivalent dose). Combined with the Kaneka QH form advantage, this is the bottle most likely to move bloodwork measurements and felt-effect markers in the 40+ population where the trial evidence concentrates. Maximum real-world response score reflects the stacked-absorption advantage in the specific population where CoQ10 actually moves the needle.
“Higher absorption than standard ubiquinol with PrimaVie shilajit.”
Keller 2014 (PMID 24891990) published the bioavailability data showing Kaneka ubiquinol + PrimaVie shilajit produced ~29-39% higher peak plasma CoQ10 versus ubiquinol alone at equivalent oral doses in healthy adults. The claim is grounded in published RCT-style PK data, not marketing extrapolation. Real, replicated, and the meaningful differentiator that justifies the premium price.
“Supports mitochondrial energy production.”
CoQ10 is the lipid-soluble electron shuttle between Complex I/II and Complex III of the mitochondrial electron transport chain — every aerobic ATP molecule depends on it. The mitochondrial-energy framing is mechanistically accurate and well-supported by the broader CoQ10 literature. Standard claim, fully verifiable mechanism.
“Promotes heart health.”
Real CoQ10 effect supported by Q-SYMBIO (Mortensen 2014, PMID 25282031) in CHF specifically and Rosenfeldt 2007 BP meta. The 'heart health' framing is generic marketing language; the specific evidence concentrates on CHF mortality and statin myopathy, not on 'general heart health' in healthy adults. Accurate in spirit, oversimplified for marketing.
“Patent-grade Kaneka QH ubiquinol — the most-studied form.”
Life Extension is on Kaneka's QH licensed-products registry. The 'most-studied' framing is accurate when referencing ubiquinol specifically — Kaneka QH is the Japanese fermentation-derived raw material used in the foundational PK paper (Hosoe 2007), the form-comparison head-to-head (Zhang 2018), and the majority of ubiquinol clinical trials. Real, verifiable, accurate.
“Trusted longevity-brand formulation.”
Life Extension has a verifiable 40+ year track record in longevity-focused supplement formulation, in-house clinical-research arm, and editorial publication that frames products through specific longevity-protocol lenses. The brand-trust claim is real for buyers who value the longevity-research positioning. 'Trusted' is subjective; the underlying track record is documented.
Most absorption-carrier claims in the CoQ10 category are marketing extrapolation — Qunol's polysorbate-80 surfactant, BioPerine in budget ubiquinone products, proprietary 'micelle' formulations. PrimaVie is different: Keller 2014 (PMID 24891990) ran a head-to-head pharmacokinetic comparison and measured ~29-39% higher peak plasma CoQ10 versus Kaneka ubiquinol alone at equivalent oral doses in healthy adults. The mechanism is proposed to combine fulvic acid electron-shuttle co-factor activity with mineral-rich support for the downstream Q10 biosynthesis pathway. Real data, replicated in subsequent work — the shilajit carrier is one of the few absorption claims in this category that survives published-evidence scrutiny.
Life Extension Super Ubiquinol is the only product on the list that stacks three layers of patent provenance on one supplement-facts panel: licensed Kaneka QH ubiquinol (the most-trial-evidenced form), licensed PrimaVie shilajit (the only standardised shilajit form with published PK data), and Life Extension's own 40+ year longevity-focused QC discipline. Each layer is independently verifiable — Kaneka's QH registry, Natreon's PrimaVie registry, Life Extension's per-batch testing summaries available on request. For the buyer where chain-of-custody matters (clinical protocols, longevity-research-anchored stacks), this is the strongest combined provenance in the consumer category.
Both Life Extension and Jarrow ship the identical 100 mg licensed Kaneka QH ubiquinol — the form, the patent provenance, and the trial-evidence anchor are interchangeable. The Life Extension premium ($45 vs Jarrow $28) buys you the PrimaVie shilajit carrier (~29-39% absorption gain) plus the broader brand pedigree. For under-50 buyers on the 100 mg/day longevity baseline, Jarrow's MCT carrier-oil softgel already closes most of the fasted-absorption gap and the marginal shilajit gain is small in absolute terms. For 50+ buyers, statin users with significant myalgia, or anyone running a deliberate longevity-stack protocol, the absorption premium scales — every percentage point matters more at older ages where endogenous Q10 has declined more. The premium is justified for the specific buyer; overkill for the casual user.
A common stacking mistake: buy Life Extension Super Ubiquinol for the PrimaVie shilajit advantage, then add a generic shilajit standalone supplement 'for the broader benefits'. Two problems: (1) heavy-metal contamination risk with non-PrimaVie shilajit is real and documented — generic Himalayan shilajit from undisclosed sources has had concerning lead, mercury, and arsenic levels. The PrimaVie supply chain mitigates this; generic suppliers don't. (2) The shilajit dose in Life Extension's softgel (100 mg) is calibrated to the Q10-absorption mechanism, not to standalone shilajit endpoints (testosterone support, fatigue, etc.) which typically use 200-500 mg/day standalone doses. If you want shilajit benefits beyond Q10 absorption, buy PrimaVie standalone — don't stack untested generic shilajit on top of this bottle.
The dose math: 1 softgel/day delivers 100 mg ubiquinol + 100 mg shilajit, which produces ~29-39% higher peak plasma Q10 versus ubiquinol-alone at the same dose. 2 softgels/day delivers 200 mg + 200 mg — the ubiquinol scaling is linear (peak plasma roughly doubles), but the shilajit absorption-carrier benefit doesn't scale linearly because the saturable transport mechanisms hit ceiling effects at higher carrier doses. Practically: 2 softgels/day is the right dose for established statin myopathy or anyone running 200 mg/day protocols, but the per-mg cost-effectiveness drops sharply. For high-dose protocols, many buyers run 1 Life Extension softgel/day (premium baseline) + 1 Jarrow softgel/day (cost-efficient stacking) — getting both benefits without doubling the Life Extension cost.
Life Extension Super Ubiquinol CoQ10 is what we recommend to the 50+ buyer running a deliberate longevity stack, the statin user with significant myalgia willing to pay for measurable absorption gains, and anyone whose protocol is anchored to Life Extension's curated longevity ecosystem. The licensed Kaneka QH + PrimaVie shilajit combination delivers ~29-39% higher peak plasma CoQ10 versus ubiquinol alone (Keller 2014) — a published, replicated bioavailability advantage that no other consumer bottle matches. Combined with Life Extension's 40+ year longevity-research brand pedigree and three-layer chain-of-custody (Kaneka + PrimaVie + LE QC), this is the highest-quality CoQ10 product money can buy in the consumer category. The two reasons to look past Life Extension: (1) You're 40-49 on a 100 mg/day longevity baseline where the absorption-carrier premium is small in absolute terms — Jarrow (#1) at $28/month covers this with marginal real-world difference. (2) Cost per active mg is your primary constraint — Healthy Origins (#6) ships the same licensed Kaneka QH at $21/month, saving $24/month for the buyer where the shilajit carrier isn't a priority. The premium is real but specific. You're paying for: (a) the only published-RCT-grade absorption-carrier stack in the category, (b) the longevity-research brand positioning that most aligns with deliberate longevity protocols, and (c) the broader Life Extension ecosystem if you're already running their multivitamin, fish oil, and other staples. For the target buyer — 50+, longevity-stack focused, willing to pay for measurable absorption gains — this is the right answer. For everyone else, the next-tier-down picks deliver 90% of the benefit at 60-70% of the cost.
Check Life Extension · Kaneka QH ubiquinol + PrimaVie shilajit · 60 softgels on AmazonThe default ubiquinol pick at $28/month — same licensed Kaneka QH, no shilajit carrier, MCT carrier-oil softgel. The right call for 40-49 buyers on the 100 mg longevity baseline where shilajit's marginal benefit doesn't justify the premium.
See it on the list →The Kaneka QH value pick at $21/month — same patent-grade ubiquinol molecule as Life Extension and Jarrow, no carrier stack, 50%+ cheaper. The right call when cost per active mg matters more than absorption optimisation.
See it on the list →The budget ubiquinone pick at $15/month — for under-40 buyers whose conversion enzyme works, this delivers the same bioactive endpoint as ubiquinol at one-third the cost. Wrong form for the 50+ target buyer though.
See it on the list →Head-to-head pharmacokinetic comparison of Kaneka ubiquinol with and without PrimaVie shilajit carrier in healthy adults. The shilajit-paired arm produced approximately 29-39% higher peak plasma CoQ10 versus ubiquinol alone at equivalent oral doses. The reference paper that anchors Life Extension's PrimaVie-stacked formulation.
Pharmacokinetic study of Kaneka ubiquinol in healthy adults — established the dose-response curve and bioavailability advantage of the reduced form. The foundational PK paper for the Kaneka QH that Life Extension ships as the ubiquinol base of this formulation.
Head-to-head trial of ubiquinol vs ubiquinone in older men showing significantly higher plasma CoQ10 in the ubiquinol arm at equivalent oral doses. Confirms the 2-4× bioavailability advantage of the reduced form in adults 40+ — the primary justification for Life Extension's ubiquinol form choice.
420 chronic heart failure patients randomised to 3×100 mg/day Kaneka CoQ10 vs placebo for 2 years. CoQ10 group showed 43% reduction in major adverse cardiovascular events and significant reduction in cardiovascular mortality. The pivotal outcome trial that anchors the Life Extension CHF-protocol dose.
Meta-analysis of 12 RCTs (n=575) on CoQ10 supplementation in statin users with myopathy. Pooled effect showed significant reduction in statin-induced muscle pain, weakness, cramps, and tiredness — the 200 mg/day dose protocol that justifies Life Extension's 2-softgel statin-support recommendation.
Comprehensive review of CoQ10 in aging, cardiovascular disease, neurodegeneration, and statin-induced complications. Establishes the age-related decline curve (~50% drop by age 60 in heart and skeletal muscle) and the rationale for high-bioavailability ubiquinol supplementation in 50+ adults — the population Life Extension's premium positioning targets.
One free quiz · personalized AI Coach path · 4 missions this week. Build your character, build your life.
